A 38-year-old woman presents with major depressive disorder and comorbid generalized anxiety disorder. She has no significant past medical history and is not on any other medications. Which antidepressant is the drug of choice for this presentation?

Explanation

## Rationale for Sertraline as Drug of Choice **Key Point:** SSRIs are universally recognized as the **first-line pharmacotherapy** for both major depressive disorder (MDD) and generalized anxiety disorder (GAD). Sertraline, in particular, is one of the most widely recommended SSRIs for comorbid depression and anxiety due to its favorable efficacy, tolerability, and broad FDA-approval profile. ### Why Sertraline? Sertraline is an SSRI (selective serotonin reuptake inhibitor) with: - **FDA approval** for MDD, panic disorder, OCD, PTSD, social anxiety disorder, and premenstrual dysphoric disorder - Excellent tolerability with a low side-effect burden compared to TCAs and SNRIs - Minimal drug-drug interactions (lower CYP450 inhibition than fluoxetine) - Extensive evidence base supporting use in comorbid anxiety-depression Per **NICE guidelines**, **APA guidelines**, and **KD Tripathi (8th ed., Ch. 12)**, SSRIs are the first-line agents for depression with comorbid anxiety. Sertraline and escitalopram are consistently cited as preferred SSRIs due to their tolerability and broad-spectrum anxiolytic-antidepressant efficacy. ### Comparison of Options | Drug | Class | MDD | GAD | First-Line Status | Notes | |---|---|---|---|---|---| | **Sertraline** | SSRI | ✓✓ | ✓✓ | **Yes — preferred** | Broad FDA approvals, well tolerated | | Venlafaxine | SNRI | ✓✓ | ✓✓ | Second-line / alternative | Valid but not universally *the* DOC; BP monitoring needed | | Fluoxetine | SSRI | ✓✓ | ✓ | Yes | Activating; longer half-life; less preferred for anxiety | | Amitriptyline | TCA | ✓✓ | ✓✓ | No — third-line | Anticholinergic burden, cardiac risk, narrow therapeutic window | ### Why Not Venlafaxine as *the* DOC? Venlafaxine (SNRI) is a valid and effective agent for comorbid MDD + GAD, but: - Current **APA and NICE guidelines** list SSRIs (sertraline, escitalopram) as **first-line**, with SNRIs as equally acceptable alternatives — not as superior or preferred agents - Venlafaxine requires blood pressure monitoring (noradrenergic activity raises BP) - The claim that SNRIs are categorically superior to SSRIs for anxiety-depression comorbidity is **not supported** by head-to-head trial evidence **Clinical Pearl:** Fluoxetine, while an SSRI, is considered more "activating" and may worsen anxiety initially, making sertraline a better choice in anxious patients. Amitriptyline is reserved for treatment-resistant cases or specific indications (neuropathic pain, migraine prophylaxis). **High-Yield:** For NEET PG/INI-CET, SSRIs — especially sertraline — are the **drug of choice** for MDD with comorbid anxiety disorders. SNRIs are acceptable alternatives but are not the primary first-line choice per standard guidelines (KD Tripathi 8e, Harrison's 21e Ch. 466).